Nkarta, Inc. (NKTX)
NASDAQ: NKTX · Real-Time Price · USD
2.700
-0.010 (-0.37%)
At close: Sep 1, 2026, 4:00 PM EDT
2.600
-0.100 (-3.70%)
Pre-market: Sep 2, 2026, 7:14 AM EDT
Nkarta Employees
Nkarta had 106 employees as of June 30, 2026. The number of employees decreased by 4 or -3.64% compared to the same quarter last year.
Employees
106
Change
-4
Growth
-3.64%
Revenue / Employee
n/a
Profits / Employee
-$1,106,830
Market Cap
193.39M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 106 | -4 | -3.64% |
| Mar 31, 2026 | 108 | -1 | -0.92% |
| Dec 31, 2025 | 108 | -49 | -31.21% |
| Sep 30, 2025 | 105 | -54 | -33.96% |
| Jun 30, 2025 | 110 | -40 | -26.67% |
| Mar 31, 2025 | 109 | -41 | -27.33% |
| Dec 31, 2024 | 157 | 7 | 4.67% |
| Sep 30, 2024 | 159 | -8 | -4.79% |
| Jun 30, 2024 | 150 | -19 | -11.24% |
| Mar 31, 2024 | 150 | -15 | -9.09% |
| Dec 31, 2023 | 150 | -13 | -7.98% |
| Sep 30, 2023 | 167 | 21 | 14.38% |
| Jun 30, 2023 | 169 | 42 | 33.07% |
| Mar 31, 2023 | 165 | 30 | 22.22% |
| Dec 31, 2022 | 163 | 27 | 19.85% |
| Sep 30, 2022 | 146 | 13 | 9.77% |
| Jun 30, 2022 | 127 | 11 | 9.48% |
| Mar 31, 2022 | 135 | 28 | 26.17% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Innate Pharma | 164 |
| Immunic | 100 |
| Alpha Cognition | 71 |
| Armata Pharmaceuticals | 61 |
| Korro Bio | 57 |
| NovaBridge Biosciences | 30 |
| Cue Biopharma | 29 |
| Satellos Bioscience | 21 |
NKTX News
- 16 days ago - Nkarta price target lowered to $10 from $11 at Stifel - TheFly
- 22 days ago - Nkarta price target lowered to $14 from $16 at H.C. Wainwright - TheFly
- 22 days ago - Nkarta reports Q2 EPS (54c), consensus (36c) - TheFly
- 22 days ago - Nkarta Earnings release: Q2 2026 - Filings
- 22 days ago - Nkarta Quarterly report: Q2 2026 - Filings
- 5 weeks ago - Cyllene Therapeutics Expands Leadership Team to Support Corporate Growth and Clinical Product Development - GlobeNewsWire
- 2 months ago - Nkarta Transcript: H.C. Wainwright 4th Annual Cell Therapy Virtual Conference - Transcripts
- 2 months ago - Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference - GlobeNewsWire